ABSTRACT
Objectives: Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS) is a heterogeneous category of fine needle aspiration cytology (FNAC); the management of this condition remains controversial. The clinical significance of such patients relies on the exclusion of malignancy. In this study, we aimed to determine the validity of the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) (2017) for predicting malignancy in this specific category of patients. Methods: In this study, we analysed a cohort of patients from our previous retrospective study. This four-year retrospective cohort study included all cases undergoing surgery with a cytological diagnosis of AUS/FLUS. We enrolled 110 cases with documented final histopathological diagnoses and ultrasound examinations. Results: The study included 83 females (75.5%) and 27 males (24.5%). The overall risk of malignancy (ROM) for AUS/FLUS thyroid nodules was 47.3%. The ROMs of TI-RADS 3 (TR3), TI-RADS 4 (TR4), and TI-RADS 5 (TR5) were 43.5%, 49.4% and 40%, respectively. There was no significant association between TI-RADS and final pathological analysis. Conclusions: Repeated FNAC with initial AUS/FLUS nodules is crucial. Our findings showed that ACR TI-RADS did not contribute to the cancer risk stratification of AUS/FLUS nodules. A large prospective multi-institutional study is now required to determine the validity of ACR TI-RADS and whether other adjunct clinical, cytological, molecular, or biochemical tools could facilitate the management of patients with these heterogeneous nodules.
ABSTRACT
Primary CNS vasculitis is an inflammatory brain disease commonly misdiagnosed affecting the medium and small vessels of the CNS. Due to its broad and non-specific clinical and radiological manifestations; Its diagnosis remains challenging. New diagnostic tools and biomarkers which increase specificity and facilitate the diagnosis for patients with suspected vasculitis are highly desirable to enable physicians to start therapy that can alter its potential aggressive course like immunosuppressant. This case report highlights the potential role of 18F-choline PET/MRI as a novel imaging tool that might help in the right clinical scenario in the diagnosis of this disease. Furthermore, it speculates on its secondary role in monitoring the response to immunosuppressant therapy.
ABSTRACT
OBJECTIVE: This study examined the diagnostic accuracy of myocardial perfusion scintigraphy (MPS) in end-stage renal disease (ESRD) patients and the incidence and clinical and biochemical predictors of myocardial perfusion abnormalities. METHODS: We evaluated 500 asymptomatic ESRD patients on hemodialysis referred for MPS for cardiac risk stratification before renal transplant surgery. Patients with abnormal MPS and an additional few patients without abnormal MPS underwent invasive coronary angiography (ICA). RESULTS: Sixty-nine patients (13%) showed abnormal MPS (reversible or fixed defect). The majority of patients had cardiovascular risk factors. There were statistically significant differences in age, male gender, hypertension, diabetes, hypercholesterolemia, and left ventricular ejection fraction (LVEF) (P < 0.05 for each) between patients with normal and abnormal MPS. Multivariate regression analysis showed that age (≥ 62 years) and low LVEF (≤ 47%) were independent predictors for abnormal MPS. ICA was performed in 112 subjects; the sensitivity, specificity, positive predictive value, and negative predictive value of MPA to detect CAD is 72%, 70%, 79%, and 61%, respectively. CONCLUSIONS: In ESRD, the incidence of myocardial perfusion defects is 13%. In addition to other traditional CAD risk factors, such as diabetes and hypertension, age, and LVEF are the strongest predictors of MPS abnormalities. Initial risk stratification can be cost-effective for identifying high-risk patients who will benefit from more imaging with CAD risk factors and LVEF. In ESRD patients, MPS diagnostic performance is relatively poor. To further evaluate the utility of MPS in diagnosis and risk stratification in ESRD, more data is therefore required.